Management
Malcolm A. Meyn, Ph.D, MSHS
Malcolm A. Meyn, Ph.D, MSHS
Malcolm A. Meyn, Ph.D, MSHS
Co-founder and Chief Scientific Officer Malcolm Meyn is the Chief Scientific Officer of Amalgent Therapeutics. Malcolm began his career as an academic scientist researching the complex systems that regulate how cells and organisms respond to chemical signals. In 2011, he took his skills to industry and began to focus on developing biolog
Co-founder and Chief Scientific Officer Malcolm Meyn is the Chief Scientific Officer of Amalgent Therapeutics. Malcolm began his career as an academic scientist researching the complex systems that regulate how cells and organisms respond to chemical signals. In 2011, he took his skills to industry and began to focus on developing biologic and small drug therapeutics. At Amalgent Therapeutics, Malcolm oversees all research and development programs, supports business development, assists in strategic decision making, and sits on the Board of Directors.
Sam Tetlow, MBA
Malcolm A. Meyn, Ph.D, MSHS
Malcolm A. Meyn, Ph.D, MSHS
Co-founder President, Executive Chair Sam is Founder and CEO of Grant Engine, a technology consulting firm focused on providing grant writing and other advisory services to university-based inventors and entrepreneurs. He identified the opportunity at Amalgent with Malcolm, and began the Company in 2020. Sam is an active angel investor and member of RTP Capital and Carolina Angel Network.
Gerald Klein, MD
Malcolm A. Meyn, Ph.D, MSHS
Andrew Graham, CFO
Chief Medical Officer
Gerald has over 35 years of medical expertise and a strong background in clinical affairs, he has contributed to the success of multiple companies.
Andrew Graham, CFO
Malcolm A. Meyn, Ph.D, MSHS
Andrew Graham, CFO
Chief Finance Officer
Andrew has over 20 years of experience, including Big Four expertise with EY, and a successful track record as CFO across more than five companies.
Advisory Board
Dr. Gillian Schmitz, MD
Dr. Gillian Schmitz, MD
Dr. Gillian Schmitz, MD
- Associate Professor of Military and Emergency Medicine Uniformed Services, University of the Health Sciences
- Vice Chair of Education, Brooke Army Medical Center
Charles Argoff, MD
Dr. Gillian Schmitz, MD
Dr. Gillian Schmitz, MD
- Director Comprehensive Pain Program, Albany Medical Center
- Department of Neurology
Peter Barton Hutt
Dr. Gillian Schmitz, MD
Frank Porecca, PhD
- Chief Council for FDA
- World Expert on Food & Drug Law
- National Academy of Sciences
Frank Porecca, PhD
June Almenoff MD, PhD, FACP
Frank Porecca, PhD
- Chair, Department of Pharmacology, University of Arizona School of Medicine
- Author of over 500 publication focused on pain or associated condition
Timothy Wright
June Almenoff MD, PhD, FACP
June Almenoff MD, PhD, FACP
A proven executive and healthcare industry veteran with more than 30 years of experience in the pharmaceutical, biotech and medical devices industries, Tim has been instrumental in building, transforming and strategically positioning organizations, driving them for growth and profitability across many diverse and highly competitive markets.
June Almenoff MD, PhD, FACP
June Almenoff MD, PhD, FACP
June Almenoff MD, PhD, FACP
Most recently served as President, Principal Executive Officer, and Chief Medical Officer at Furiex, a company acquired by Actavis for $1.2 billion. Furiex was responsible for the development of Viberzi, a treatment for diarrhea-predominant irritable bowel syndrome (IBS-D), which received FDA approval in 2015, followed by approval from the EMA.
Partners
East Carolina University
This opioid adjuvant technology being commercialized at Amalgent was invented by Dr. Kori Brewer and Dr. Stefan Clemens at East Carolina University in Greenville, NC. At ECU, Dr. Brewer is the Associate Chief, Division of Research in the Department of Emergency Medicine and Dr. Clemens is Associate Professor of Physiology. Amalgent is privileged to have continued input from the ECU team as we work to bring the technology to market.